Dr Rischin talks to ecancer at ASCO 2025 about C-POST, a phase 3, double-blind, multicenter trial, evaluated cemiplimab as an adjuvant therapy in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiotherapy.

Patients considered high risk—due to specific nodal or non-nodal criteria—were randomized to receive cemiplimab or placebo. The study's primary endpoint, disease-free survival (DFS), was improved with cemiplimab, with a hazard ratio of 0.32 and a 24-month DFS rate of 87% compared to 64% with placebo.

Dr Rischin notes that cemiplimab also improved freedom from local-regional recurrence and distant recurrence. These benefits were observed regardless of PD-L1 expression status.